1. Home
  2. SKIN vs BMEA Comparison

SKIN vs BMEA Comparison

Compare SKIN & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SKIN

The Beauty Health Company

N/A

Current Price

$0.82

Market Cap

117.4M

ML Signal

N/A

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

N/A

Current Price

$1.26

Market Cap

95.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SKIN
BMEA
Founded
1997
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Package Goods/Cosmetics
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
117.4M
95.4M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
SKIN
BMEA
Price
$0.82
$1.26
Analyst Decision
Buy
Strong Buy
Analyst Count
4
6
Target Price
$2.03
$9.83
AVG Volume (30 Days)
6.0M
1.0M
Earning Date
05-07-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
55.56
69.19
EPS
N/A
N/A
Revenue
$300,790,000.00
N/A
Revenue This Year
$0.88
N/A
Revenue Next Year
$4.60
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.55
$0.87
52 Week High
$2.69
$2.99

Technical Indicators

Market Signals
Indicator
SKIN
BMEA
Relative Strength Index (RSI) 51.57 43.56
Support Level $0.81 $1.23
Resistance Level $0.92 $1.48
Average True Range (ATR) 0.12 0.09
MACD 0.00 -0.01
Stochastic Oscillator 30.06 16.13

Price Performance

Historical Comparison
SKIN
BMEA

About SKIN The Beauty Health Company

SkinHealth Systems Inc is a world-wide medical aesthetics company delivering an integrated ecosystem of clinically validated solutions designed to help consumers achieve superior skin health and support the success of providers. Its brands are Hydrafacial and SkinStylus.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

Share on Social Networks: